233 related articles for article (PubMed ID: 21376569)
21. Optimizing the use of trabectedin for advanced soft tissue sarcoma in daily clinical practice.
Le Cesne A; Reichardt P
Future Oncol; 2015; 11(11 Suppl):3-14. PubMed ID: 26043310
[TBL] [Abstract][Full Text] [Related]
22. The Danish experience with trabectedin treatment for metastatic sarcoma: Importance of hyponatremia.
Schack LH; Mouritsen LS; Elowsson C; Krarup-Hansen A; Safwat A
Acta Oncol; 2015 Jan; 54(1):34-40. PubMed ID: 25263179
[TBL] [Abstract][Full Text] [Related]
23. What makes real world outcomes in soft tissue sarcomas? A mono-institutional trabectedin experience.
Moriceau G; Vallard A; Méry B; Rivoirard R; Langrand-Escure J; Espenel S; Ben Mrad M; Wang G; Diao P; Fournel P; Collard O; Magné N
Bull Cancer; 2015 Oct; 102(10):814-22. PubMed ID: 26384694
[TBL] [Abstract][Full Text] [Related]
24. Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial.
Lorusso D; Scambia G; Pignata S; Sorio R; Amadio G; Lepori S; Mosconi A; Pisano C; Mangili G; Maltese G; Sabbatini R; Artioli G; Gamucci T; Di Napoli M; Capoluongo E; Ludovini V; Raspagliesi F; Ferrandina G
Ann Oncol; 2016 Mar; 27(3):487-93. PubMed ID: 26681678
[TBL] [Abstract][Full Text] [Related]
25. Trabectedin in advanced soft tissue sarcoma: case series.
Demirci U; Buyukberber S; Yetisyigit T; Dizdar O; Benekli M; Alkis N; Coskun U;
J BUON; 2012; 17(3):591-2. PubMed ID: 23033305
[TBL] [Abstract][Full Text] [Related]
26. Trabectedin: novel insights in the treatment of advanced sarcoma.
Lopez JP; Gajdos C; Elias A
Curr Oncol Rep; 2014 Jun; 16(6):387. PubMed ID: 24756367
[TBL] [Abstract][Full Text] [Related]
27. Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program.
Blay JY; Italiano A; Ray-Coquard I; Le Cesne A; Duffaud F; Rios M; Collard O; Bertucci F; Bompas E; Isambert N; Chaigneau L; Cassier P; Bui B; Decanter G; Derbel O; Coindre JM; Zintl P; Badri N; Penel N
BMC Cancer; 2013 Feb; 13():64. PubMed ID: 23388156
[TBL] [Abstract][Full Text] [Related]
28. Trabectedin for sarcomas in daily clinical practice: analysis of 45 patients treated in a French institution.
Daupin J; Paubel P; Fillon J; Debrix I; Soares DG; Lotz JP
J Chemother; 2016 Dec; 28(6):494-499. PubMed ID: 27535294
[TBL] [Abstract][Full Text] [Related]
29. Trabectedin in patients with metastatic soft tissue sarcoma: a retrospective single center analysis.
Schur S; Lamm W; Köstler WJ; Hoetzenecker K; Nemecek E; Schwameis K; Klepetko W; Windhager R; Brodowicz T
Anticancer Drugs; 2013 Aug; 24(7):725-30. PubMed ID: 23728219
[TBL] [Abstract][Full Text] [Related]
30. Trabectedin for advanced soft tissue sarcomas: a single institution experience.
Gounaris I; Hatcher HM; Davidson D; Sherbourne K; Alam S; Zaki KA; Horan G; Earl HM
Future Oncol; 2014 Aug; 10(11):1843-51. PubMed ID: 24450573
[TBL] [Abstract][Full Text] [Related]
31. Trabectedin for the treatment of advanced metastatic soft tissue sarcoma.
Simpson EL; Rafia R; Stevenson MD; Papaioannou D
Health Technol Assess; 2010 May; 14 Suppl 1():63-7. PubMed ID: 20507805
[TBL] [Abstract][Full Text] [Related]
32. Going further in the knowledge of Yondelis®; what's new in daily clinical practice?
Blay JY
Future Oncol; 2014 Jun; 10(8 Suppl):s13-7. PubMed ID: 25048044
[TBL] [Abstract][Full Text] [Related]
33. Single nucleotide polymorphisms in nucleotide excision repair genes XPA, XPD, XPG and ERCC1 in advanced colorectal cancer patients treated with first-line oxaliplatin/fluoropyrimidine.
Monzo M; Moreno I; Navarro A; Ibeas R; Artells R; Gel B; Martinez F; Moreno J; Hernandez R; Navarro-Vigo M
Oncology; 2007; 72(5-6):364-70. PubMed ID: 18204222
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of trabectedin for advanced sarcomas in clinical trials versus compassionate use programs: analysis of 92 patients treated in a single institution.
Fayette J; Boyle H; Chabaud S; Favier B; Engel C; Cassier P; Thiesse P; Méeus P; Sunyach MP; Vaz G; Ray-Coquard I; Ranchère D; Decouvelaere AV; Alberti L; Pérol D; Blay JY
Anticancer Drugs; 2010 Jan; 21(1):113-9. PubMed ID: 19887935
[TBL] [Abstract][Full Text] [Related]
35. 13 years of trabectedin, 5 years of Yondelis®: what have we learnt?
Le Cesne A
Expert Rev Anticancer Ther; 2013 Jun; 13(6 Suppl 1):11-9. PubMed ID: 23638726
[TBL] [Abstract][Full Text] [Related]
36. Trabectedin therapy for sarcomas.
Casali PG; Sanfilippo R; D'Incalci M
Curr Opin Oncol; 2010 Jul; 22(4):342-6. PubMed ID: 20489618
[TBL] [Abstract][Full Text] [Related]
37. Lack of Correlation Between Liver Tests Abnormalities and Trabectedin Efficacy in the Treatment of Soft Tissue Sarcoma: a Retrospective Study.
Vincenzi B; Stumbo L; Maltese G; Cerbone L; Spalato Ceruso M; Badalamenti G; Santini D; Tonini G; Frezza AM; De Lisi D; Silletta M
Sci Rep; 2015 Aug; 5():12077. PubMed ID: 26235506
[TBL] [Abstract][Full Text] [Related]
38. Trabectedin for the treatment of breast cancer.
D'Incalci M; Zambelli A
Expert Opin Investig Drugs; 2016; 25(1):105-15. PubMed ID: 26592307
[TBL] [Abstract][Full Text] [Related]
39. Diagnostic use of fluorescence in situ hybridization in expert review in a phase 2 study of trabectedin monotherapy in patients with advanced, translocation-related sarcoma.
Sugita S; Asanuma H; Hasegawa T
Diagn Pathol; 2016 Apr; 11():37. PubMed ID: 27068820
[TBL] [Abstract][Full Text] [Related]
40. [Trabectedin registry].
Kubácková K; Fínek J; Vyzula R; Zvaríková M; Vocka M; Batko S; Dreslerová J; Lazarov PP; Lysý M; Ptátková Z; Benesová V; Bortlícek Z; Kandrnal V
Klin Onkol; 2011; 24(6):470-4. PubMed ID: 22257238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]